Compare MHO & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MHO | HAE |
|---|---|---|
| Founded | 1976 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.8B |
| IPO Year | 1995 | 1996 |
| Metric | MHO | HAE |
|---|---|---|
| Price | $122.20 | $56.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $160.00 | $84.13 |
| AVG Volume (30 Days) | 195.5K | ★ 769.7K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.54 |
| EPS | ★ 2.55 | 2.46 |
| Revenue | ★ $4,417,781,000.00 | $910,373,000.00 |
| Revenue This Year | $0.66 | N/A |
| Revenue Next Year | $6.97 | $5.23 |
| P/E Ratio | $49.69 | ★ $23.28 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $103.52 | $47.32 |
| 52 Week High | $158.92 | $87.32 |
| Indicator | MHO | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 38.38 | 47.91 |
| Support Level | $117.91 | $54.92 |
| Resistance Level | $140.08 | $62.48 |
| Average True Range (ATR) | 3.86 | 3.07 |
| MACD | -0.87 | 0.01 |
| Stochastic Oscillator | 0.00 | 50.45 |
M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprises a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.